Please provide your email address to receive an email when new articles are posted on . Of 20 hospitals providing insulin algorithms, 60% stated which patients should initiate basal or nutritional ...

Type 1 diabetes affects 46.3 million people worldwide, and the number of people affected increases by about 3% each year. It requires careful calculations of insulin needs and bothersome daily ...

Insulin titration in type 2 diabetes involves systematic adjustment of insulin doses to achieve and maintain optimal blood glucose levels while minimising hypoglycaemia. Traditional approaches rely on ...

MILPITAS, Calif.--(BUSINESS WIRE)--Bigfoot Biomedical (Bigfoot), a leader in developing intelligent connected injection support systems, today announced the acquisition of a reinforcement learning ...

The Food and Drug Administration has cleared the Beta Bionics iLet ACE Pump and the iLet Dosing Decision Software for people six years of age and older with Type 1 diabetes. These two devices, along ...

Bigfoot Biomedical is doing its part to ensure that the possibility of building a smarter diabetes management system is more than just an urban legend. The tech maker has purchased a new algorithm ...

Looking to the European market, digital therapeutics company Amalgam Rx has scored an E.U. CE Mark for its insulin titration algorithm, called iSage Rx, and its white-label variants. This comes more ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The Omnipod 6 automated insulin delivery algorithm met ...

Hospitalized patients with complex dietary restrictions often develop hyperglycemia, or high blood sugar. This occurs in roughly one-quarter to one-half of these patients and can lead to serious ...

A University of Virginia Center for Diabetes Technology-developed algorithm – paired with a continuous glucose monitor – can help users better manage their type 2 diabetes by recommending insulin-dose ...

Initiators of biosimilar insulin glargine-yfgn were more likely to reside in rural areas, live in long-term care facilities, or have multiple prescribers and were less likely to have previously used ...